RT Journal Article
SR Electronic
T1 Antibody response patterns in COVID-19 patients with different levels of disease severity—Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.20.20231696
DO 10.1101/2020.11.20.20231696
A1 Imai, Kazuo
A1 Kitagawa, Yutaro
A1 Tabata, Sakiko
A1 Kubota, Katsumi
A1 Nagura-Ikeda, Mayu
A1 Matsuoka, Masaru
A1 Miyoshi, Kazuyasu
A1 Sakai, Jun
A1 Ishibashi, Noriomi
A1 Tarumoto, Norihito
A1 Takeuchi, Shinichi
A1 Ito, Toshimitsu
A1 Maesaki, Shigefumi
A1 Tamura, Kaku
A1 Maeda, Takuya
YR 2020
UL http://medrxiv.org/content/early/2020/11/23/2020.11.20.20231696.abstract
AB Background We analyzed antibody response patterns according to level of disease severity in patients with novel coronavirus disease 2019 (COVID-19) in Japan.Methods We analyzed 611 serum specimens from 231 patients with COVID-19 (mild, 170; severe, 31; critical, 30). IgM and IgG antibodies against nucleocapsid protein (N) and spike 1 protein (S1) were detected by enzyme-linked immunosorbent assays.Findings The peaks of fitting curves for the OD values of IgM and IgG antibodies against N appeared simultaneously, while those against S1 were delayed compared with N. The OD values of IgM against N and IgG against both N and S1 were significantly higher in the severe and critical cases than in the mild cases at 11 days after symptom onset. The seroconversion rates of IgG were higher than those of IgM against both N and S1 during the clinical course based on the optimal cut-off values defined in this study. The seroconversion rates of IgG and IgM against N and S1 were higher in the severe and critical cases than in the mild cases.Conclusion Our findings show that a stronger antibody response occurred in COVID-19 patients with greater disease severity and there were low seroconversion rates of antibodies against N and S1 in the mild cases. The antibody response patterns in our population suggest a second infection pattern, leading us to hypothesize that cross-reactivity occurs between SARS-CoV-2 and past infection with other human coronaviruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or nonprofit sectors. The corresponding author had full access to all study-related data and had final responsibility for the decision to submit the study for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of Saitama Medical University (approval number 1917), Institutional Review Board of Saitama Medical University Hospital (approval numbers 20064.01 and 20001), and Institutional Review Board of the Self-Defense Forces Central Hospital (approval number 01-011).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data used in this study is available from the corresponding author upon reasonable request.